Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Milliarden-Deal stärkt Lockheed Martin - Spekulationen belasten Rheinmetall, RENK & HENSOLDT (Finanzen.net) +++ HENSOLDT Aktie +3,21%

VIVORYON Aktie

 >VIVORYON Aktienkurs 
1.345 EUR    +0.4%    (TradegateBSX)
Ask: 1.345 EUR / 2500 Stück
Bid: 1.34 EUR / 500 Stück
Tagesumsatz: 4812 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
VIVORYON Aktie über LYNX handeln
>VIVORYON Performance
1 Woche: +2,9%
1 Monat: -4,5%
3 Monate: -14,2%
6 Monate: -18,8%
1 Jahr: -28,2%
laufendes Jahr: -7,7%
>VIVORYON Aktie
Name:  VIVORYON THERAP. EO-,01
Land:  Niederlande
Sektor:  Gesundheit
ISIN/ Wkn:  NL00150002Q7 / A2QJV6
Symbol/ Ticker:  05Y (Frankfurt)
Kürzel:  FRA:05Y, ETR:05Y, 05Y:GR
Index:  -
Webseite:  https://www.vivoryon.com/
Profil:  Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and potential commercialization of small molecule-based medicines that modulate the activity and stability of pathologically altered ..
>Volltext..
Marktkapitalisierung:  38.93 Mio. EUR
Unternehmenswert:  -
Umsatz:  -
EBITDA:  -
Nettogewinn:  -
Gewinn je Aktie:  -
Schulden:  -
Liquide Mittel:  -
Operativer Cashflow:  -
Bargeldquote:  -
Umsatzwachstum:  -
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  VIVORYON
Letzte Datenerhebung:  10.04.26
>VIVORYON Kennzahlen
Aktien/ Unternehmen:
Aktien: 29.61 Mio. St.
Frei handelbar: 78.78%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 15
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 373.48%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -
Eigenkaprendite: -
>VIVORYON Peer Group
Gesundheit, Antikörper- Behandlung, Lebererkrankungen & -behandlung/ Hepatitis, Neurologie/ psychische Behandlung/ Schlaganfälle, Demenz/ Alzheimer- Behandlung, Nierenerkrankungen & -behandlung, Onkologie/ Krebs- Behandlung
 
09.04.26 - 07:03
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference (GlobeNewswire EN)
 
Vivoryon attend the Van Lanschot Kempen Life Sciences Conference....
28.03.26 - 07:02
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology (GlobeNewswire EN)
 
New data analyses from the Company's varoglutamstat Phase 2 program were presented at the World Congress of Nephrology....
07.01.26 - 07:03
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences (GlobeNewswire EN)
 
the Company's management will participate in the following medical and investor conferences....
04.12.25 - 16:01
Vivoryon Therapeutics: Kostensenkungen und F&E-Fokus prägen Q3 2025 (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 07:03
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates (GlobeNewswire EN)
 
Q3 2025 Financial Results and Business Updates...
25.11.25 - 07:03
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025...
06.11.25 - 17:33
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025...
03.11.25 - 07:03
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences...
06.10.25 - 20:51
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million (GlobeNewswire EN)
 
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW....
04.09.25 - 07:03
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates...
27.08.25 - 07:03
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025...
27.06.25 - 07:03
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences...
24.06.25 - 15:03
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting...
17.06.25 - 07:01
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress...
11.06.25 - 07:03
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025...
06.06.25 - 09:48
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025...
27.05.25 - 07:03
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat...
13.05.25 - 07:03
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025 (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025...
29.04.25 - 07:03
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update...
24.04.25 - 18:03
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million (GlobeNewswire EN)
 
Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Gemeinsame Beschäftigungen und Liebhabereien sind das Erste, worin sich eine wechselseitige Übereinstimmung hervortut. - Johann Wolfgang von Goethe
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!